Bsense Bio nominates dual Kv7.2/3 and TRPV1 ion channel modulator as clinical candidate for chronic pain
Dec. 7, 2023
Bsense Bio Therapeutics Ltd. has nominated BSEN-760, a dual Kv7.2/3 and TRPV1 ion channel modulator, as a clinical candidate for the treatment of chronic pain.
